ClinicalTrials.gg
CompletedNCT06359132TeleConvert-AFUpdated Oct 13, 2026

mHealth Rhythm Management in Terms of Cancelling Unnecessary Scheduled ECVs in Presumed Persistent AFpatients.

An observational study in Atrial Fibrillation, Arrhythmia and Mobile Health, sponsored by Maastricht University Medical Center. Completed at 2 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Maastricht University Medical Center · Observational

How we know

Updated Oct 13, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
270
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Atrial Fibrillation by Maastricht University Medical Center — 4 open to participants now, 4 under way, none of them phase 3. Atrial Fibrillation · Maastricht University Medical Center.

Started
2022
with 1 other
Observational
5 of 16
2 open now
Registered
15th of 16
by date

Among the 16 studies in Atrial Fibrillation by Maastricht University Medical Center, this one is one of 2 that started in 2022, is one of 5 observational ones, and was the 15th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

4 of the 16 studies in Atrial Fibrillation by Maastricht University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Atrial Fibrillation by Maastricht University Medical Center, or all of them as a file.
02

Study summary

Despite a clear definition in the European Society of Cardiology (ESC) guidelines, the differentiation between paroxysmal (self-terminating) and persistent (nonself- terminating) atrial fibrillation (AF) remains challenging in clinical practice. Some patients with presumed persistent AF are planned for electrical cardioversion (ECV) but appear to have a paroxysmal pattern or present in sinus rhythm (SR) at the scheduled ECV appointment. This results in unnecessary visits or interventions for patients, and costs and burden for the hospitals and health insurances. Based on the feasibility of the TeleCheck-AF approach, which is an on-demand mobile health (mHealth) infrastructure incorporating app-based heart rate and rhythm monitoring to support remote AF management through teleconsultation, the investigators aim to extend this mHealth approach to the management of presumed persistent AF patients planned for ECV.

Read the detailed description

When putted on the waiting list for ECV (at baseline), the case-coordinator (investigator or nurse) will contact the patient and provide an mHealthprescription, manual and app-activation QR-code to use the CE-marked mobile phone app using photoplethysmography (PPG) technology through the built-in mobile phone's camera to monitor rate and rhythm. After 24-hours the case-coordinator will check whether the patient activated the app, otherwise will contact patient for further support.

Recordings from the device will be sent to a secure cloud application. This cloud application is equipped with an automatic analyses algorithm with a red-amber-green alert system. Patients will be asked to use the app 3-times a day and in case of symptom onset and disappearance while being on the waiting list for ECV. In case of amber alert (recording in asystole > 5 sec, tachycardia > 170 bpm, bradycardia 110 bpm) the subject's care team will be notified of the alert by the investigators within one workday. The subject will then be contacted by the care team to intensify rate control if necessary. Subjects also have the possibility to contact the investigators directly if needed. In case of green alert (SR recording), the investigators will process the alert within one workweek. The subject will then be contacted by the investigators to visit the hospital and execute a 12-lead ECG to confirm SR as soon as possible. When SR is confirmed by ECG, scheduled ECV will be cancelled by the treating physician and rate/rhythm control medication might be intensified, this is part of standard care. When SR is not confirmed by ECG, treatment decisions will remain to the treating physician and he/she will decide whether or not to cancel scheduled ECV (based on PPG recordings). In the 4-weeks following scheduled ECV appointment, all patients will receive remote semi-continuous app-based rate/rhythm monitoring including red-amber- green alert notifications and will be asked to use the app 3-times a day and in case of symptom onset and disappearance. In case of an amber alert, the subject's care team will be notified of the alert by the investigators within one workday. The subject will then be contacted by the care team to intensify rate control if necessary. Subjects also have the possibility to contact the investigators directly if needed. Of importance is that alerts will only be assessed by the investigators during office hours. Patients will specifically (both verbally and written) be informed that in case of alarming symptoms during or outside of office hours, emergency services or their own general practitioner should be contacted. In all cases of acute emergencies, a patient should contact the emergency services. Furthermore, patients will be asked to fulfill a self-composed questionnaire based on the System Usability Scale extended with additional questions to assess the usability and user-friendliness of the refined TeleCheck-AF approach around ECV at 4-week follow-up. Also a self-composed questionnaire based on the HADS-A scale will be used to assess anxiety while using the mHealth-based refined TeleCheck-AF approach around ECV at four weeks.

03

Conditions studied

  • Atrial Fibrillation
  • Arrhythmia
  • Mobile Health
  • Electrical Cardioversion

Keywords

  • Atrial fibrillation
  • Arrhythmia
  • Mobile health
  • Electrical cardioversion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with presumed persistent AF, age ≥18 years, scheduled for ECV, and in possession of a smartphone will be included in this study from January 2022 to January 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presumed persistent AF
  • Scheduled for ECV
  • Age ≥18 years
  • Smartphone possession
  • Ability and willing to sign
  • Ability and willing to use mobile phone app (FibriCheck)

Exclusion criteria

Exclusion Criteria:

  • Deemed unsuitable for participation by attending physician
  • Presence of an active implanted electronic cardiac device
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
270 participants (actual)
Patient registry
No

Groups and cohorts

  • TeleConvert-AF

    Patients with presumed persistent AF, age ≥18 years, scheduled for ECV, and in possession of a smartphone will be included in this study from January 2022 to January 2025.

06

What researchers measure

Primary outcomes

  1. The number of cancelled unnecessary scheduled ECV appointments in patients with presumed persistent AF scheduled for ECV unnecessary scheduled ECV appointments

    The number of cancelled unnecessary scheduled ECV appointments in patients with presumed persistent AF scheduled for ECV

    Time frame: through study completion, an average of 8 weeks

Secondary outcomes

  1. Number of patients that agreed the refined TeleCheck-AF approach is usable and userfriendly as assessed by the System Usability Scale questionnaire extended with additional questions

    Number of patients that agreed the refined TeleCheck-AF approach is usable and userfriendly as assessed by the System Usability Scale questionnaire extended with additional questions

    Time frame: through study completion, an average of 8 weeks

  2. Number of patients that agreed the refined TeleCheck-AF approach is anxious as assessed by the HADS-A scale questionnaire

    Number of patients that agreed the refined TeleCheck-AF approach is anxious as assessed by the HADS-A scale questionnaire

    Time frame: through study completion, an average of 8 weeks

  3. Amount of saved costs for the hospitals and health insurances by using the TeleCheck-AF approach preceding ECV in terms of cancelling unnecessary scheduled ECV appointments

    Amount of saved costs for the hospitals and health insurances by using the TeleCheck-AF approach preceding ECV in terms of cancelling unnecessary scheduled ECV appointments

    Time frame: through study completion, an average of 8 weeks

  4. Number of patients with paroxysmal AF

    Number of patients with paroxysmal AF assessed by the refined by the on-demand heart rate and rhythm monitoring application

    Time frame: through study completion, an average of 8 weeks

  5. Time to recurrence of AF

    Time to recurrence of AF

    Time frame: up to 4 weeks after ECV

  6. Time period of monitoring heart rate and rhythm using the mHealth-based application

    Time period of monitoring heart rate and rhythm using the mHealth-based application

    Time frame: through study completion, an average of 8 weeks

  7. Amount of burden for the hospitals and health insurances by using the TeleCheck-AF approach preceding ECV in terms of cancelling unnecessary scheduled ECV appointments

    Amount of burden for the hospitals and health insurances by using the TeleCheck-AF approach preceding ECV in terms of cancelling unnecessary scheduled ECV appointments

    Time frame: through study completion, an average of 8 weeks

07

Study locations

2 sites
  • Maastricht University Medical Center
    Maastricht, Limburg, Netherlands
  • Viecuri Medical Center
    Venlo, Limburg, Netherlands
08

References and documents

Publications

  • Engels MDEA, Hermans ANL, Hermans BJM, Luermans J, Chaldoupi SM, Hendriks JML, Lankveld T, Kessels MVM, Vorstermans BJGH, Beukema RJ, Vernooy K, Heesen W, Linz DK. Smartphone application-based heart rhythm monitoring to cancel scheduled electrical cardioversion in patients with spontaneous conversion of presumed persistent atrial fibrillation: TeleConvert-AF. Eur Heart J Digit Health. 2025 Dec 9;7(2):ztaf140. doi: 10.1093/ehjdh/ztaf140. eCollection 2026 Mar. PubMed 41624561 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jun 2025, 35 months.

Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's 35 months is below that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Jan 2022 → Jul 2022, primary completion Jan 2025 → Jun 2025 and completion Jan 2025 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2024
First posted
Apr 11, 2024
StartActual
Jul 1, 2022was Jan 2022
Primary completionActual
Jun 1, 2025was Jan 2025
CompletionActual
Jun 1, 2025was Jan 2025
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 13, 2026
Start date
Jan 1, 2022→Jul 1, 2022
Oct 13, 2026
Primary completion
Jan 1, 2025→Jun 1, 2025 (actual)
Oct 13, 2026
Study completion
Jan 1, 2025→Jun 1, 2025 (actual)
Oct 13, 2026
Enrollment
264 (estimated)→270 (actual)
Oct 13, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41624561 ↗
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41624561 ↗
    Start date Jan 1, 2022→Jul 1, 2022
    Primary completion Jan 1, 2025→Jun 1, 2025 (now actual)
    Study completion Jan 1, 2025→Jun 1, 2025 (now actual)
    Enrollment 264 (estimated)→270 (actual)
    + 4 other changes: verification date, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06359132
Responsible party
Sponsor
First posted
Apr 11, 2024
Start date
Jul 1, 2022
Primary completion
Jun 1, 2025
Completion
Jun 1, 2025
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion